Acrux Limited (ASX:ACR) has announced the appointment of Yelda Adal-Hall as Chief Financial Officer and Lachie Mallia of Bio101 as Company Secretary, with both appointments taking effect on 25 November 2026 following the company's Annual General Meeting.

Key Points

  • Yelda Adal-Hall appointed as Chief Financial Officer, effective 25 November 2026
  • Lachie Mallia, Director at Bio101, appointed as Company Secretary, effective 25 November 2026
  • Joanna Johnson, who currently holds both roles, will depart the company at the conclusion of the AGM
  • Acrux has decided to separate the CFO and Company Secretary roles as part of the transition
  • Lachie Mallia will be responsible for communications between the company and ASX under ASX Listing Rule 12.6

Appointment of Yelda Adal-Hall as Chief Financial Officer

Yelda Adal-Hall brings more than 25 years of experience across commercial and not-for-profit organisations to the CFO role. She has previously held senior finance leadership positions at Telspec Australia, Orica (ICI), The Reach Foundation, and the Catholic Archdiocese of Melbourne. Her expertise spans financial strategy, reporting, business planning, treasury, governance, and risk management. She is a Fellow Certified Practising Accountant (FCPA) and a member of CPA Australia. The filing states she has extensive experience advising boards and executive teams on financial performance, strategic planning, and risk.

Appointment of Lachie Mallia as Company Secretary

Lachie Mallia is a Chartered Accountant with qualifications in accounting, banking and finance, and governance practice. He holds the position of Director at Bio101, described in the filing as a specialist provider of company secretarial services with extensive experience in the pharmaceutical sector. The filing states he has extensive experience in financial and management accounting, company administration, and taxation, and currently acts as CFO and Company Secretary for several life sciences companies. Under ASX Listing Rule 12.6, Mallia will be responsible for communications between Acrux and the ASX.

Departure of Joanna Johnson and Role Separation

The filing states that the appointments follow the resignation of Joanna Johnson, who currently holds both the CFO and Company Secretary positions. Johnson will depart at the conclusion of the company's Annual General Meeting. Acrux has decided to separate the two roles as part of the transition. CEO John Warmbrunn said in the filing: "Separating the CFO and Company Secretary roles will allow us to draw on their respective expertise while maintaining our focus on progressing Female Testosterone MDTS towards commercialisation." Warmbrunn also acknowledged Johnson's contribution and service to the company.